Background: Rectal Chlamydia trachomatis infections represent one of the most common sexually transmitted infections in the MSM population. Although current treatment guidelines suggest the use of either azithromycin or doxycycline, several clinical studies reported on azithromycin treatment failures in the case of rectal C. trachomatis localizations. In this context, the biological reasons behind the lack of azithromycin efficacy for C. trachomatis infections at the rectal level are still poorly understood.
Introduction
Chlamydia trachomatis genovars D through to K represent the agents of the most common bacterial sexually transmitted infection worldwide. 1 Urogenital C. trachomatis infections (i.e. urethritis and cervicitis) are often asymptomatic and, if left untreated, can lead to several complications, including pelvic inflammatory disease, tubal infertility and epididymo-orchitis. 2 Besides urogenital localizations, C. trachomatis can be found at extra-genital sites, such as pharyngeal and rectal mucosa, particularly in the MSM population. 3 In considering the frequent asymptomatic nature of extra-genital C. trachomatis infections, they can act as an important reservoir for further transmission. 4 In the absence of a chlamydial vaccine, public health control of C. trachomatis infections relies primarily on effective, accessible and affordable antimicrobial treatment, combined with appropriate prevention, diagnostics and epidemiological surveillance.
In this context, international guidelines suggest, as recommended regimens for urogenital C. trachomatis infections, the use of either 1 g of azithromycin orally in a single dose or 100 mg of doxycycline orally twice a day for 7 days. Erythromycin and quinolones (i.e. levofloxacin or ofloxacin) represent alternative regimens. 5, 6 For rectal infections, several non-randomized clinical studies showed higher efficacy rates for doxycycline (98.8%-100%) than for azithromycin (74%-87%) at this anatomical site. [6] [7] [8] Considering the important limitations of these studies and the low quality of data supporting the superiority of doxycycline over azithromycin, both regimens continue to be recommended as first-line for treating rectal infections. 6 Randomized controlled trials will probably allow to better compare the efficacy of azithromycin versus doxycycline for the treatment of rectal infections. 9 Although recently it has been suggested that azithromycin treatment failure can be associated with high bacterial loads, 10 the reasons behind its failure in rectal C. trachomatis localizations are still poorly understood. To understand better the biological basis of these findings, the aim of this study was to evaluate the in vitro antimicrobial susceptibility of several C. trachomatis strains in two different cell lines, providing a simplified model of both the urogenital localization and the rectal site of infection. In particular, the susceptibility to macrolides (azithromycin and erythromycin), doxycycline and levofloxacin was assessed for 20 C. trachomatis strains, belonging to the most frequently reported genovars (D, E, F and G), 3, 11 both in human endocervical cells (HeLa cells) and in colorectal cells (Caco-2 cells). Moreover, a correlation between MIC values and C. trachomatis bacterial load was investigated in both cell lines.
Materials and methods

C. trachomatis strains and genotyping
A total of 20 C. trachomatis strains were tested. Of these, four were reference strains: serovar E strain Bour (ATCC V R -VR-348B), serovar D strain UW-3/Cx (ATCC V R -VR-885), serovar F strain IC-Cal-3 (ATCC V R -VR-346) and serovar G strain UW-57/Cx (ATCC V R -VR-878). The remaining 16 were randomly selected from a broad collection of strains isolated during the years 2005 and 2008 in the Microbiology Unit, S. Orsola Hospital, Bologna (Italy). In particular, these strains were recovered from urethral swabs (n " 9) of male patients with non-gonococcal urethritis and from cervical swabs (n " 7) of women with cervicitis. 12 At the time of C. trachomatis isolation, all the patients were not under antibiotic treatment and most of them (70%) were symptomatic, complaining about various urogenital disorders (dysuria, genital discharge and dyspareunia). When C. trachomatis infection was diagnosed the subjects were treated with doxycycline twice a day for 7 days.
After the isolation, C. trachomatis strains were propagated for 2/3 weeks in LLC-MK2 cells (ATCC V R CCL-7 TM ). Afterwards, C. trachomatis elementary bodies (EBs) were purified from cell debris and reticulate bodies by Renografin density gradient centrifugation, 13 harvested in sucrosephosphate-glutamate (SPG) buffer and stored at #80 C until use. The infectivity titre of each C. trachomatis strain was determined by a serial dilution method, inoculating suitable dilutions into susceptible cell cultures and calculating the number of inclusions inside the host cells. The infectivity titre of EBs was expressed as the number of inclusion-forming units (IFUs)/mL.
C. trachomatis molecular genotyping was performed for the clinically isolated strains by omp1 gene sequencing, as previously described. 12 Globally, six genovar E strains, five genovar D strains, five genovar G strains and four genovar F strains were included in the study.
Cell lines
Experiments were conducted using both HeLa cells (ATCC
, an epithelial cell line originating from a human cervix adenocarcinoma, and Caco-2 cells (ATCC V R HTB-37 TM ), epithelial cells derived from a colorectal adenocarcinoma (kindly provided by Dr Elisa Michelini, FaBiT, University of Bologna, Italy).
Cells were grown to confluent monolayers in individual tubes containing sterile coverslips in 5% CO 2 at 37 C. The cell lines were cultivated in DMEM (EuroClone, Pero, Italy), supplemented with 10% fetal bovine serum and 1% L-glutamine, without antibiotics. In the case of antimicrobial susceptibility testing, 1 mg/mL of cycloheximide was added to the medium.
Antimicrobial susceptibility
The antimicrobial drugs levofloxacin (GlaxoSmithKline, Verona, Italy), doxycycline, erythromycin and azithromycin (Sigma-Aldrich, Milan, Italy) were provided as powders and solubilized according to the manufacturers' instructions. Antimicrobial susceptibility testing was performed in both HeLa cells and Caco-2 cells, as described elsewhere with slight modifications. 14, 15 The confluent cell monolayers were inoculated with a total of 5%10 3 IFUs of each C. trachomatis strain. In particular, a single SPG aliquot of purified EBs stored at #80 C was thawed slowly in ice and vigorously vortexed. Afterwards, the stock solution was diluted with SPG to a concentration of 5%10 4 IFUs/mL and 100 lL (corresponding to 5%10 3 IFUs) was added to each of the individual tubes, containing 900 lL of antibiotic-free medium. After centrifugation at 1700 g for 1 h, the medium was removed and replaced with medium containing scalar concentrations of the different antimicrobial drugs. The concentrations tested for each antimicrobial ranged as follows: levofloxacin from 0.06 to 2 mg/L, doxycycline from 0.006 to 2 mg/L, erythromycin from 0.006 to 4 mg/L and azithromycin from 0.003 to 2 mg/L. After incubation at 37 C for 48 h, infected monolayers were washed with PBS, fixed with methanol and stained with a monoclonal antibody against the chlamydial lipopolysaccharide antigen conjugated with fluorescein (Meridian, Cincinnati, OH, USA). The MIC was defined as the lowest concentration able to reduce the number of chlamydial inclusions .90%, compared with the level of drug-free controls. When evaluating the number of inclusions, both 'aberrant' inclusions (small but intensely bright inclusions lacking granularity) and 'normal' inclusions (large chlamydial vacuoles displaying a high degree of granularity) were taken into account.
The MBC values were measured by aspirating the antibiotic-containing medium, washing the monolayer twice with PBS and re-incubating in antibiotic-free medium for 48 h at 37 C. Afterwards, cell monolayers were fixed and stained as described before. The MBC was the lowest concentration of the drug reducing .90% of chlamydial inclusions after the reincubation of monolayers in antimicrobial-free medium. Each experiment was run in triplicate.
Correlation between MIC and C. trachomatis IFUs
Azithromycin and doxycycline MICs were determined as previously described, using different amounts of C. trachomatis IFUs (5%10 
Statistical analysis
The mean number of IFUs/microscopic field at %200 magnification + SD was compared between Caco-2 cells and HeLa cells in drug-free controls, by means of a paired t-test. 
Results
Antimicrobial susceptibility
In drug-free controls, a significantly higher number of chlamydial IFUs was noticed in Caco-2 cells compared with HeLa cells (mean number of IFUs/microscopic field at %200 magnification + SD: 195+23.3 versus 117+22.0; P , 0.0001). Table 1 shows the MIC and MBC values of the antimicrobial agents tested for the 20 C. trachomatis strains, subdivided on the basis of the different genovars. In both cell lines, except for levofloxacin, showing MICs comparable to MBCs, the other antimicrobial drugs were characterized by MBC values two to four times the MICs. No significant differences were noticed between different C. trachomatis genovars.
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Globally, for all the strains, macrolides show higher MIC and MBC values (2-fold dilutions) in Caco-2 cells compared with HeLa cells, whereas for doxycycline and levofloxacin, no significant differences were found between the two cell lines.
Correlation between MIC and C. trachomatis IFUs
At the different C. trachomatis IFU amounts, azithromycin and doxycycline MICs in HeLa cells did not differ significantly (P " 0.36 and 0.45, respectively), as well as doxycycline MICs in Caco-2 cells (P " 0.82). On the contrary, MICs of azithromycin in Caco-2 cells were higher, with the increasing level of C. trachomatis IFUs (P , 0.0001). Detailed results are shown in Figure 1 .
Discussion
C. trachomatis rectal infections represent one of the commonest sexually transmitted infections in the MSM population, with increasing detection rates also in women. 3, 4 Although current treatment guidelines recommend either azithromycin or doxycycline, there are increasing concerns about treatment failure with azithromycin in the case of rectal localizations. [6] [7] [8] [9] Considering that the reasons behind the lack of azithromycin efficacy for rectal C. trachomatis infection are poorly understood, the aim of this study was to evaluate if a different antimicrobial susceptibility was present on the basis of the different cell targets, in a simplified model of the infection both at the urogenital site and at the rectal level.
For this purpose, we tested the antimicrobial drugs recommended for C. trachomatis infection treatment (azithromycin, doxycycline, erythromycin, levofloxacin) against 20 C. trachomatis strains, belonging to different genovars, using epithelial cells of endocervical and of colorectal origin.
When tested in HeLa cells, C. trachomatis strains showed MIC and MBC values comparable to those reported recently by a nationwide surveillance in Japan. 15 Azithromycin showed a greater activity against C. trachomatis strains compared with doxycycline, as already stated. 16 Moreover, we found that the antimicrobial susceptibility levels were comparable for D through to G genovars. Although Zheng et al. 16 found a 2-4-fold MIC difference between C. trachomatis genovars, we confirmed the homogeneous data of antimicrobial susceptibility reported by Donati et al. 14 Interestingly, all the C. trachomatis strains, regardless of the genovar, showed higher MIC and MBC values of macrolides in Caco-2 cells compared with HeLa cells, in contrast to doxycycline and levofloxacin. In addition, looking for a correlation between MICs and C. trachomatis IFU amounts, we noticed that azithromycin MICs seemed to be significantly higher with increasing levels of EBs on Caco-2 cells.
Similarly, Suchland et al. 17 demonstrated that MIC/MBC values of macrolides can be affected by the cell line used, whereas in the presence of tetracycline, doxycycline and ofloxacin, Chlamydia susceptibility was comparable with all the cell lines. Moreover, in line with our findings, they found no difference in doxycycline MICs, when the inoculum ranged between 300 and 300 000 IFUs/well. 17 It is known that many laboratory conditions, such as pH, temperature, nutrients present in the media, polarity of the cell type Table 1 . Antimicrobial susceptibility of Chlamydia trachomatis JAC and cytokine secretion by infected cells, may affect the ability of a particular antimicrobial to penetrate intracellularly and exert its action, leading to variations in C. trachomatis susceptibility.
18
Even though a different activity of azithromycin in Caco-2 cells and HeLa cells cannot be totally ruled out (e.g. different cell permeability), it has been shown that high and sustained concentrations of azithromycin are found in rectal tissue following a single 1 g dose, suggesting that inadequate concentrations are unlikely to cause treatment failure. 19 Besides the intracellular uptake of the antimicrobials, additional variables can influence the results of Chlamydia susceptibility testing, such as the interval between the establishment of the infection and the drug administration, or the endpoint used for defining the MIC values. 17 Moreover, factors, such as the long-term storage of chlamydial isolates, the multiple culture passaging of strains and the different adaptation on cell lines, can affect the growth characteristics and the fitness and the virulence of chlamydial isolates, thus leading to variations in antimicrobial susceptibility levels. 17, 18 Although it is impossible to rule out that some of these factors could have affected our results, important points of our experimental design should be highlighted: (i) the main objective of this study was to compare the MICs/MBCs in two different cell lines, rather than to obtain absolute values; (ii) all the strains were processed in parallel in the two cell lines; and (iii) all the C. trachomatis strains included in the study were not previously adapted to grow in HeLa cells and Caco-2 cells, allowing to avoid imbalances due to the bacterial fitness in a particular cell line.
Considering all the aspects mentioned above, we hypothesized that our findings could be ascribed to the peculiar replication model of C. trachomatis in the different epithelial cells.
Effectively, in drug-free controls, C. trachomatis strains showed a significantly higher infectivity in Caco-2 cells compared with HeLa cells, as suggested by a considerable increase of inclusion number.
Our results are in line with those previously reported for animal strains, showing an increase in number and inclusion size when Chlamydia suis and Chlamydia pecorum were cultivated in Caco-2 cells, opposite to other epithelial cells. 20 The higher azithromycin MICs found in Caco-2 cells, together with the positive correlation between MICs and C. trachomatis IFUs, could explain azithromycin treatment failure for C. trachomatis infections at the rectal site, where higher bacterial loads have been found. 10 We are fully aware that cell lines cannot sufficiently mimic the in vivo pathogen-host interactions and only the use of more complex and advanced models (e.g. three-dimensional polarized cell-line models, various tissue engineered anatomical constructs) will shed light on C. trachomatis behaviour in the rectal site.
Anyway, to our knowledge, this is the first report evaluating the antimicrobial susceptibility of C. trachomatis in a cell line of colorectal origin and it could be of aid to understand the biological basis of azithromycin treatment failure for C. trachomatis rectal infections. Foschi et al.
